$ACUTAAS Financial performance and key operating metrics (consolidated) Operating Revenue for Q1FY27 is Rs. 330 Crs., 59.08% growth YoY, Total Income is Rs. 331 Crs., 48.53% growth YoY, Gross Profit is Rs. 191 Crs., 73% growth YoY, EBITDA is Rs. 113 Crs., 122.08% growth YoY, EBITDA Margin is 34.29% improved by 973 basis points YoY, PBT Rs. 104 Crs., 78.91% growth YoY, PAT Rs. 75 Crs. 70.39% growth YoY. On QoQ basis Op. Revenue is down by 23.82%, Total Income is down by 25.32%, Gross Profit is down by 28.85%, EBITDA is down by 38.39%, EBITDA Margin also reduced by 811 BPS, PBT is down by 43.47% and PAT is also down by 44.15%. EBITDA Margin expansion driven by gross margin expansion (“higher contribution from pharma intermediate business”) plus “operational efficiencies.” CDMO grew strongly and “core pharmaceutical intermediate business also delivered a robust growth. Specialty Chemicals “gradually phasing out commodity chemicals… replacing them with newer higher margin products.” FY27 revenue growth guidance reaffirmed: 25% revenue growth with stable margins.

#WatchOutFor#MacroViews#EquityResearch#TrendingSectors#FundamentalViews

992 likes·65 comments